Home > > Asia And Global Viral Conjunctivitis Pipeline Drugs Market- Size, Share, Growth Rate, and Forecast
The Asia Viral Conjunctivitis Pipeline Drugs market was valued at $911.9 Million in 2023, and is projected to reach $1,189.2 Million by 2030 growing at a CAGR of 3.92% from 2024 to 2030. DST-100 segment is expected to be the highest contributor to this market, with $590.2 Million in 2023, and is anticipated to reach $735.5 by 2030, registering a CAGR of 3.24%. APD-209 segment is anticipated to reach $453.7 Million by 2030 with the highest CAGR of 5.08%. Drug Type DST-100 APD-209 BY REGION North America U.s. Canada Europe Germany U.k. France Italy Spain Rest of Europe Asia China Japan South Korea India Singapore Rest of Asia Middle East & Africa Brazil Mexico South Africa Australia Rest of MENA